BMS 214662

Drug Profile

BMS 214662

Latest Information Update: 16 Jan 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Benzodiazepines; Imidazoles; Small molecules
  • Mechanism of Action Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Haematological malignancies; Non-small cell lung cancer

Most Recent Events

  • 16 Jan 2008 No development reported - Phase-I for Cancer in USA (IV)
  • 16 Jan 2008 No development reported - Phase-I for Haematological malignancies in USA (IV-infusion)
  • 16 Jan 2008 No development reported - Phase-II for Non-small cell lung cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top